Emerging technology presentation demonstrates use of AC5-GTM in submucosal lifting and management of gastrointestinal bleeding during porcine endoscopic procedures. Surgeons, clinicians and other ...

FRAMINGHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is ...

FRAMINGHAM, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today ...

FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will ...

FRAMINGHAM, Mass., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, ...

Abrams joined the company on Monday ahead of taking over the CFO role on Monday, May 10, according to a release from Arch. He will replace current CFO Richard Davis, who will remain with the company ...

WELLESLEY, MA -- (Marketwired) -- 01/06/15 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, obtained positive results from ...

Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly ...

Short interest for Arch Therapeutics Inc gives investors a sense of the degree to which investors are betting on the decline of Arch Therapeutics Inc's stock. Short interest data is updated every two ...

FRAMINGHAM, MA--(Marketwired - Feb 27, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and ...